Drugs / Xinnaoning Capsule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03914131 | May 2018 → Dec 2019 | intermediate coronary syndrome | Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xinnaoning Capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03914131 ↗ |
| Known as | XNN | “Xinnaoning (XNN) capsule is considered as an effective adjuvant treatment for CSA with the efficacy of promoting qi and blood circulation but lack of high-quality clinical evidence.” PMID 31374015 ↗ Aug 2019 |
| Route | Oral | “Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.” NCT03914131 ↗ |